バイオロジクスCDMOの世界市場レポート 2025年

バイオロジクスCDMO市場規模は、今後数年で急成長が見込まれます。2029年にはCAGR14.8％で423億3,000万米ドルに成長します。予測期間の成長は、生物学的製剤に対する需要の増加、バイオシミラーやバイオベッターの出現、バイオ製造インフラへの投資、複雑なプロセスのアウトソーシングへのシフト、サプライチェーンの回復力とリスク軽減への注力、規制の調和、承認の迅速化などに起因すると考えられます。予測期間における主な動向としては、エンド・ツー・エンドのソリューションを提供する能力の拡大、シングルユース技術の採用、連続製造プロセスの統合、専門CDMOの出現などが挙げられます。

細胞治療と遺伝子治療の需要の急増は、今後のバイオロジクスCDMO市場の成長を促進すると予想されます。細胞療法と遺伝子療法は、生きた細胞や遺伝物質を利用して細胞や遺伝子のレベルで根本的な病気の原因に対処する革新的な医療アプローチであり、従来の医薬品では管理が難しかったり不治の病であったりする症状に対する潜在的な治療法を提供します。根本的な遺伝的・細胞的原因に対処することで、疾患に対する革新的な治療法を提供できる可能性があるため、細胞・遺伝子治療の需要は高まっています。生物学的CDMOは、生きた細胞、ウイルスベクター、遺伝子マテリアルの取り扱いに関する専門知識を提供し、細胞・遺伝子治療の安全かつ効率的な生産を促進すると同時に、バイオ医薬品企業が規制要件や技術的課題を克服するのを支援することで、研究から臨床応用への移行を促進します。例えば、2023年1月、米国を拠点とする主要な専門家会員組織である米国遺伝子・細胞治療学会（ASGCT）によると、遺伝子・細胞・RNA治療パイプラインは2022年に7％の伸びを示し、開発中の治療法は合計3,726種類に達しました。このうち55％が遺伝子治療、22％が非遺伝子組み換え細胞治療、23％がRNA治療です。したがって、細胞治療と遺伝子治療に対する需要の急増が、バイオロジクスCDMO市場の成長を牽引しています。

バイオロジクスCDMO市場で事業を展開する主要企業は、バイオ医薬品の開発と製造の効率と能力を高めるために、新しい細胞株などの技術的に高度なソリューションを開発しています。この技術は、免疫療法の研究開発の課題に対応し、効力が強化された治療用抗体を生産します。例えば、2023年11月、医薬品およびバイオテクノロジー分野に特化したスイスの製造会社であるロンザグループは、糖分子であるフコースを100％含まず、他の性能特性を損なうことなく効力を高めた抗体を生産するように設計されたGS Effex細胞株を発売しました。この細胞株は、抗体治療薬の効力の増加に関連する免疫療法の研究開発の課題を克服するのに役立ちます。安定性、拡張性、生産性に優れた細胞株であり、探索段階の研究から商業生産に至るまで、治療薬開発のためのソリューションを提供します。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、コロナ、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界のバイオロジクスCDMO PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界のバイオロジクスCDMO市場：成長率分析
• 世界のバイオロジクスCDMO市場の実績：規模と成長, 2019-2024
• 世界のバイオロジクスCDMO市場の予測：規模と成長, 2024-2029, 2034F
• 世界のバイオロジクスCDMO総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のバイオロジクスCDMO市場：細胞タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 哺乳類
• 非哺乳類
• 世界のバイオロジクスCDMO市場：製品タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 生物学的製剤
• バイオシミラー
• 世界のバイオロジクスCDMO市場、タイプ別サブセグメンテーション：哺乳類、実績と予測, 2019-2024, 2024-2029F, 2034F
• チャイニーズハムスター卵巣（CHO）細胞
• ヒト胎児腎臓（HEK）細胞
• その他の哺乳類細胞
• 世界のバイオロジクスCDMO市場、タイプ別サブセグメンテーション：非哺乳類、実績と予測, 2019-2024, 2024-2029F, 2034F
• 酵母細胞
• 細菌細胞
• 昆虫細胞
• その他の非哺乳類細胞

第7章 地域別・国別分析

• 世界のバイオロジクスCDMO市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のバイオロジクスCDMO市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• バイオロジクスCDMO市場：競合情勢
• バイオロジクスCDMO市場：企業プロファイル
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • Evonik Industries AG Overview, Products and Services, Strategy and Financial Analysis
  • Sandoz International GmbH Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• ICON PLC
• Grifols SA
• Lonza Group Ltd.
• Boehringer Ingelheim International GmbH
• Catalent Inc.
• JSR Corp.
• Parexel International Corporation
• WuXi Biologics（Cayman）Inc.
• Samsung Biologics Co. Ltd.
• Emergent BioSolutions Inc.
• Rentschler Biopharma SE
• FUJIFILM Diosynth Biotechnologies U.S.A. Inc.
• Binex Co. Ltd.
• Bora Pharmaceuticals Co. Ltd
• 3P Biopharmaceuticals s.l.u

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• バイオロジクスCDMO市場2029：新たな機会を提供する国
• バイオロジクスCDMO市場2029：新たな機会を提供するセグメント
• バイオロジクスCDMO市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

A biologics contract development and manufacturing organization (CDMO) is a service provider that supports pharmaceutical companies in the development and production of biologic drugs, which include vaccines, blood and blood components, allergens, somatic cells, gene therapies, tissues, and recombinant therapeutic proteins.

The main cell types in biologics CDMO are mammalian and non-mammalian. Mammalian refers to cell lines derived from mammals, commonly used in the production of biologics and cell-based therapies due to their ability to produce complex proteins and maintain post-translational modifications. The various products types include biologics and biosimilars.

The main cell types in biologics CDMO are mammalian and non-mammalian. Mammalian refers to cell lines derived from mammals, commonly used in the production of biologics and cell-based therapies due to their ability to produce complex proteins and maintain post-translational modifications. The various products types include biologics and biosimilars.

The biologics cdmo market size has grown rapidly in recent years. It will grow from $21.3 billion in 2024 to $24.37 billion in 2025 at a compound annual growth rate (CAGR) of 14.4%. The growth in the historic period can be attributed to rise in biologics development, cost efficiency and flexibility, focus on core competencies, regulatory compliance and quality assurance, globalization of pharmaceutical supply chains.

The biologics cdmo market size is expected to see rapid growth in the next few years. It will grow to $42.33 billion in 2029 at a compound annual growth rate (CAGR) of 14.8%. The growth in the forecast period can be attributed to increasing demand for biologic therapies, emergence of biosimilars and biobetters, investments in biomanufacturing infrastructure, shift towards outsourcing complex processes, focus on supply chain resilience and risk mitigation, regulatory harmonization, and expedited approvals. Major trends in the forecast period include expansion of capabilities to offer end-to-end solutions, adoption of single-use technologies, integration of continuous manufacturing processes, emergence of specialized CDMOs.

The surge in demand for cell and genetic therapy is expected to propel the growth of the biologic CDMO market going forward. Cell and gene therapy are innovative medical approaches that utilize living cells or genetic material to address underlying disease causes at the cellular or genetic level, providing potential treatments for conditions that are difficult to manage or incurable with traditional pharmaceuticals. The demand for cell and gene therapy is rising due to their potential to offer innovative treatments for diseases by addressing underlying genetic or cellular causes. Biologic CDMOs provide expertise in handling living cells, viral vectors, and genetic material, facilitating safe and efficient production of cell and gene therapies while assisting biopharmaceutical companies in navigating regulatory requirements and technical challenges, thereby facilitating translation from research to clinical application. For instance, in January 2023, according to The American Society of Gene & Cell Therapy (ASGCT), a US-based primary professional membership organization, the gene, cell, and RNA therapy pipeline saw 7% growth in 2022, reaching a total of 3,726 therapies in development. Of these, 55% are gene therapies, while 22% are non-genetically modified cell therapies, and 23% are RNA therapies. Therefore, the surge in demand for cell and genetic therapy is driving the growth of the biologic CDMO market.

Major companies operating in the biologics CDMO market are developing technologically advanced solutions, such as new cell lines, to enhance biopharmaceutical development and manufacturing efficiency and capabilities. The technology produces therapeutic antibodies with enhanced potency, addressing immunotherapy research and development challenges. For instance, in November 2023, Lonza Group, a Switzerland-based manufacturing company that specializes in the pharmaceutical and biotechnology sectors, launched GS Effex cell lines, designed to produce antibodies that are 100% free of fucose, a sugar molecule and demonstrate increased potency without compromising on other performance attributes. It helps overcome immunotherapy research and development challenges related to the need for antibody therapeutics to increase potency. It is a stable, scalable, and productive cell line that provides a solution for therapeutic development from discovery-stage research through commercial manufacturing.

In May 2022, Bora Pharmaceuticals Co. Ltd., a Taiwan-based organization that specializes in manufacturing and selling pharmaceutical products, acquired the CDMO assets of Eden Biologics Inc. for $100 million. The aim of the acquisition is to expand its presence in the global CDMO market, particularly focusing on biologics, macromolecules, and cell and gene therapy markets. Eden Biologics Inc. is a Taiwan-based biotechnology company specializing in the contract development and manufacturing of innovative biologics for therapeutic applications.

Major companies operating in the biologics CDMO market are AbbVie Inc., Thermo Fisher Scientific Inc., Novartis AG, Evonik Industries AG, Sandoz International GmbH, ICON PLC, Grifols SA, Lonza Group Ltd., Boehringer Ingelheim International GmbH, Catalent Inc., JSR Corp., Parexel International Corporation, WuXi Biologics (Cayman) Inc., Samsung Biologics Co. Ltd., Emergent BioSolutions Inc., Rentschler Biopharma SE, FUJIFILM Diosynth Biotechnologies U.S.A. Inc., Binex Co. Ltd., Bora Pharmaceuticals Co. Ltd, 3P Biopharmaceuticals s.l.u, JRS Pharma LP, J Rettenmaier and SOHNE GmbH and Co KG, Kemwell Biopharma Pvt. Ltd., Cytovance Biologics, AGC Biologics, Shenzhen Hepalink Pharmaceutical Co. Ltd.

North America was the largest region in the biologics CDMO market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biologics CDMO market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the biologics CDMO market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The biologics CDMO market consist of revenues earned by entities by providing services such as process development, analytical development, cell line development, supply chain management, and fill-finish services. The biologics CDMO market also includes sales of monoclonal antibodies, recombinant proteins, antisense and molecular therapy, and vaccines. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Biologics CDMO Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on biologics cdmo market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for biologics cdmo ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The biologics cdmo market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Cell Type: Mammalian; Non-Mammalian
• 2) By Product Type: Biologics; Biosimilars
• Subsegments:
• 1) By Mammalian: Chinese Hamster Ovary (CHO) Cells; Human Embryonic Kidney (HEK) Cells; Other Mammalian Cells
• 2) By Non-Mammalian: Yeast Cells; Bacterial Cells; Insect Cells; Other Non-Mammalian Cells
• Companies Mentioned: AbbVie Inc.; Thermo Fisher Scientific Inc.; Novartis AG; Evonik Industries AG; Sandoz International GmbH
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Biologics CDMO Market Characteristics

3. Biologics CDMO Market Trends And Strategies

4. Biologics CDMO Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Biologics CDMO Growth Analysis And Strategic Analysis Framework

• 5.1. Global Biologics CDMO PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Biologics CDMO Market Growth Rate Analysis
• 5.4. Global Biologics CDMO Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Biologics CDMO Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Biologics CDMO Total Addressable Market (TAM)

6. Biologics CDMO Market Segmentation

• 6.1. Global Biologics CDMO Market, Segmentation By Cell Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Mammalian
• Non-Mammalian
• 6.2. Global Biologics CDMO Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Biologics
• Biosimilars
• 6.3. Global Biologics CDMO Market, Sub-Segmentation Of Mammalian, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Chinese Hamster Ovary (CHO) Cells
• Human Embryonic Kidney (HEK) Cells
• Other Mammalian Cells
• 6.4. Global Biologics CDMO Market, Sub-Segmentation Of Non-Mammalian, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Yeast Cells
• Bacterial Cells
• Insect Cells
• Other Non-Mammalian Cells

7. Biologics CDMO Market Regional And Country Analysis

• 7.1. Global Biologics CDMO Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Biologics CDMO Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Biologics CDMO Market

• 8.1. Asia-Pacific Biologics CDMO Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Biologics CDMO Market, Segmentation By Cell Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Biologics CDMO Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Biologics CDMO Market

• 9.1. China Biologics CDMO Market Overview
• 9.2. China Biologics CDMO Market, Segmentation By Cell Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Biologics CDMO Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Biologics CDMO Market

• 10.1. India Biologics CDMO Market, Segmentation By Cell Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Biologics CDMO Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Biologics CDMO Market

• 11.1. Japan Biologics CDMO Market Overview
• 11.2. Japan Biologics CDMO Market, Segmentation By Cell Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Biologics CDMO Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Biologics CDMO Market

• 12.1. Australia Biologics CDMO Market, Segmentation By Cell Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Biologics CDMO Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Biologics CDMO Market

• 13.1. Indonesia Biologics CDMO Market, Segmentation By Cell Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Biologics CDMO Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Biologics CDMO Market

• 14.1. South Korea Biologics CDMO Market Overview
• 14.2. South Korea Biologics CDMO Market, Segmentation By Cell Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Biologics CDMO Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Biologics CDMO Market

• 15.1. Western Europe Biologics CDMO Market Overview
• 15.2. Western Europe Biologics CDMO Market, Segmentation By Cell Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Biologics CDMO Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Biologics CDMO Market

• 16.1. UK Biologics CDMO Market, Segmentation By Cell Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Biologics CDMO Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Biologics CDMO Market

• 17.1. Germany Biologics CDMO Market, Segmentation By Cell Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Biologics CDMO Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Biologics CDMO Market

• 18.1. France Biologics CDMO Market, Segmentation By Cell Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Biologics CDMO Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Biologics CDMO Market

• 19.1. Italy Biologics CDMO Market, Segmentation By Cell Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Biologics CDMO Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Biologics CDMO Market

• 20.1. Spain Biologics CDMO Market, Segmentation By Cell Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Biologics CDMO Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Biologics CDMO Market

• 21.1. Eastern Europe Biologics CDMO Market Overview
• 21.2. Eastern Europe Biologics CDMO Market, Segmentation By Cell Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Biologics CDMO Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Biologics CDMO Market

• 22.1. Russia Biologics CDMO Market, Segmentation By Cell Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Biologics CDMO Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Biologics CDMO Market

• 23.1. North America Biologics CDMO Market Overview
• 23.2. North America Biologics CDMO Market, Segmentation By Cell Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Biologics CDMO Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Biologics CDMO Market

• 24.1. USA Biologics CDMO Market Overview
• 24.2. USA Biologics CDMO Market, Segmentation By Cell Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Biologics CDMO Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Biologics CDMO Market

• 25.1. Canada Biologics CDMO Market Overview
• 25.2. Canada Biologics CDMO Market, Segmentation By Cell Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Biologics CDMO Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Biologics CDMO Market

• 26.1. South America Biologics CDMO Market Overview
• 26.2. South America Biologics CDMO Market, Segmentation By Cell Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Biologics CDMO Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Biologics CDMO Market

• 27.1. Brazil Biologics CDMO Market, Segmentation By Cell Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Biologics CDMO Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Biologics CDMO Market

• 28.1. Middle East Biologics CDMO Market Overview
• 28.2. Middle East Biologics CDMO Market, Segmentation By Cell Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Biologics CDMO Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Biologics CDMO Market

• 29.1. Africa Biologics CDMO Market Overview
• 29.2. Africa Biologics CDMO Market, Segmentation By Cell Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Biologics CDMO Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Biologics CDMO Market Competitive Landscape And Company Profiles

• 30.1. Biologics CDMO Market Competitive Landscape
• 30.2. Biologics CDMO Market Company Profiles
  • 30.2.1. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Evonik Industries AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Sandoz International GmbH Overview, Products and Services, Strategy and Financial Analysis

31. Biologics CDMO Market Other Major And Innovative Companies

• 31.1. ICON PLC
• 31.2. Grifols SA
• 31.3. Lonza Group Ltd.
• 31.4. Boehringer Ingelheim International GmbH
• 31.5. Catalent Inc.
• 31.6. JSR Corp.
• 31.7. Parexel International Corporation
• 31.8. WuXi Biologics (Cayman) Inc.
• 31.9. Samsung Biologics Co. Ltd.
• 31.10. Emergent BioSolutions Inc.
• 31.11. Rentschler Biopharma SE
• 31.12. FUJIFILM Diosynth Biotechnologies U.S.A. Inc.
• 31.13. Binex Co. Ltd.
• 31.14. Bora Pharmaceuticals Co. Ltd
• 31.15. 3P Biopharmaceuticals s.l.u

32. Global Biologics CDMO Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Biologics CDMO Market

34. Recent Developments In The Biologics CDMO Market

35. Biologics CDMO Market High Potential Countries, Segments and Strategies

• 35.1 Biologics CDMO Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Biologics CDMO Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Biologics CDMO Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer